All In Biotech

Drug Trial Radar · NCT03492281

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

Last checked: Nov 20, 2026Latest source record: Mar 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,530 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,530

Actual

Start

Mar 26, 2018

Primary completion

Jan 10, 2019

Study completion Feb 4, 2019

Sponsor

Lead sponsor
Urovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Apr 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.

Conditions

  • Overactive Bladder

Interventions

  • vibegronDrug

    single daily oral dose of vibegron 75 mg for 12 weeks

  • Vibegron placeboDrug

    placebo to match vibegron (experimental drug)

  • Tolterodine Tartrate ERDrug

    single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks

  • Tolterodine placeboDrug

    placebo to match tolterodine (active comparator)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) ParticipantsTime frame: Baseline (BL); Week 12
  2. CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet ParticipantsTime frame: Baseline; Week 12

Locations

215 sites in 6 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Achieve Clinical Research

    Birmingham, Alabama

  • Fundamental Research LLC

    Gulf Shores, Alabama

  • Longwood Research

    Huntsville, Alabama

  • Coastal Clinical Research Inc.

    Mobile, Alabama

  • Clinical Research Consortium

    Tempe, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Dream Team Clinical Research LLC

    Anaheim, California

  • Hope Clinical Research

    Canoga Park, California

  • Core Healthcare Group

    Cerritos, California

  • Research Center of Fresno Inc.

    Fresno, California

  • American Clinical Trials

    Hawaiian Gardens, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Grossmont Center for Clinical Research

    La Mesa, California

  • Prime-Care Clinical Research

    Laguna Hills, California

  • Long Beach Clinical Trial Services Inc.

    Long Beach, California

  • Long Beach Clinical Trials LLC

    Long Beach, California

  • Downtown L.A. Research Center Inc.

    Los Angeles, California

  • Urology Group of Southern California

    Los Angeles, California

  • Tri Valley Urology Medical Group

    Murrieta, California

  • Northern California Research

    Sacramento, California

  • San Bernadino Urological Associates

    San Bernardino, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • WR MCCCR

    San Diego, California

  • Artemis Institute for Clinical Research

    San Marcos, California

  • Empire Clinical Research

    Upland, California

  • Bayview Research Group LLC

    Valley Village, California

  • Horizons Clinical Research Center

    Denver, Colorado

  • Lynn Institute of Denver

    Denver, Colorado

  • Clinical Research Consulting LLC

    Milford, Connecticut

  • Coastal Connecticut Research LLC

    New London, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Innovative Medical Research of South Florida Inc.

    Aventura, Florida

  • PAB Clinical Research

    Brandon, Florida

  • Innovative Research of West FL Inc.

    Clearwater, Florida

  • Universal Medical and Research Center LLC

    Coral Gables, Florida

  • Top Medical Research Inc.

    Cutler Bay, Florida

  • Avail Clinical Research

    DeLand, Florida

  • Jesscan Medical Research

    Delray Beach, Florida

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.